TVTX Key Statistics, Chart & Performance
The current stock price of TVTX is 34.58 USD. In the past month the price increased by 0.58%. In the past year, price increased by 91.16%.
TVTX Latest News, Press Relases and Analysis
TVTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B |
Related stock screener links
About TVTX
Company Profile
Travere Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 385 full-time employees. The company went IPO on 2003-07-23. The firm is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Company Info
TRAVERE THERAPEUTICS INC
3611 Valley Centre Dr, Suite 300
San Diego CALIFORNIA 92130 US
CEO: Eric M. Dube
Employees: 385
Phone: 18889697879
TRAVERE THERAPEUTICS INC / TVTX FAQ
What does TRAVERE THERAPEUTICS INC do?
Travere Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 385 full-time employees. The company went IPO on 2003-07-23. The firm is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
What is the current price of TVTX stock?
The current stock price of TVTX is 34.58 USD. The price decreased by -2.87% in the last trading session.
Does TRAVERE THERAPEUTICS INC pay dividends?
TVTX does not pay a dividend.
How is the ChartMill rating for TRAVERE THERAPEUTICS INC?
TVTX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is TVTX stock listed?
TVTX stock is listed on the Nasdaq exchange.
Is TRAVERE THERAPEUTICS INC (TVTX) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TVTX.
Can you provide the market cap for TRAVERE THERAPEUTICS INC?
TRAVERE THERAPEUTICS INC (TVTX) has a market capitalization of 3.09B USD. This makes TVTX a Mid Cap stock.
TVTX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to TVTX. When comparing the yearly performance of all stocks, TVTX is one of the better performing stocks in the market, outperforming 94.4% of all stocks.
TVTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TVTX. Both the profitability and financial health of TVTX have multiple concerns.
TVTX Financial Highlights
Over the last trailing twelve months TVTX reported a non-GAAP Earnings per Share(EPS) of -1.06. The EPS increased by 75.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.44% | ||
| ROE | -120.36% | ||
| Debt/Equity | 4.23 |
TVTX Forecast & Estimates
21 analysts have analysed TVTX and the average price target is 42.33 USD. This implies a price increase of 22.41% is expected in the next year compared to the current price of 34.58.
For the next year, analysts expect an EPS growth of 87.9% and a revenue growth 116.86% for TVTX